Published in Cancer Res on July 01, 2008
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol (2009) 9.41
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol (2010) 3.86
Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol (2012) 3.50
Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol (2010) 3.38
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother (2010) 3.00
The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol (2010) 2.94
T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res (2012) 2.43
Myeloid derived suppressor cells in human diseases. Int Immunopharmacol (2011) 2.43
Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood (2010) 2.38
Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg (2012) 2.24
The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology (2013) 2.14
Resolution of inflammation: an integrated view. EMBO Mol Med (2013) 2.01
Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol (2012) 2.01
Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A (2011) 1.89
Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res (2009) 1.85
Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. Stem Cells (2010) 1.75
Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med (2011) 1.52
TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest (2012) 1.52
In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res (2011) 1.48
Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood (2011) 1.47
Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice. Hepatology (2011) 1.44
Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. J Immunol (2010) 1.38
Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer (2013) 1.35
Reciprocal relationship between myeloid-derived suppressor cells and T cells. J Immunol (2013) 1.34
Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med (2014) 1.29
Control of the immune response by pro-angiogenic factors. Front Oncol (2014) 1.26
Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin Oncol (2014) 1.26
Tumor microenvironment: a main actor in the metastasis process. Clin Exp Metastasis (2012) 1.25
Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Adv Cancer Res (2015) 1.25
STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol (2011) 1.18
Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol (2012) 1.18
Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol (2013) 1.17
Tumor-altered dendritic cell function: implications for anti-tumor immunity. Front Immunol (2013) 1.17
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev (2012) 1.16
Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron (2012) 1.15
CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. Cancer Res (2009) 1.14
NKT cell networks in the regulation of tumor immunity. Front Immunol (2014) 1.13
Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J Cancer (2012) 1.12
Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res (2014) 1.11
Antigen-specific CD4(+) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling. Cancer Res (2012) 1.10
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood (2014) 1.09
Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest (2015) 1.07
Plasticity of Ly-6C(hi) myeloid cells in T cell regulation. J Immunol (2011) 1.07
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. Front Oncol (2014) 1.04
Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron (2012) 1.03
A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells. Cell Res (2012) 1.03
Murine models of B-cell lymphomas: promising tools for designing cancer therapies. Adv Hematol (2012) 1.01
Immunosuppressive MDSCs induced by TLR signaling during infection and role in resolution of inflammation. Front Cell Infect Microbiol (2013) 1.01
CD11b(+) Gr1(+) bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice. Hepatology (2012) 1.01
Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol (2012) 1.01
Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells. J Leukoc Biol (2012) 1.00
Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. Clin Dev Immunol (2012) 0.99
Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines. Cancers (Basel) (2011) 0.99
Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients. Proc Natl Acad Sci U S A (2014) 0.99
Orchestration of angiogenesis by immune cells. Front Oncol (2014) 0.97
Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas. Oncoimmunology (2013) 0.95
Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells. Semin Cancer Biol (2012) 0.95
Myeloid derived suppressor cells: Targets for therapy. Oncoimmunology (2013) 0.94
Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. Front Oncol (2014) 0.94
Role of resveratrol-induced CD11b(+) Gr-1(+) myeloid derived suppressor cells (MDSCs) in the reduction of CXCR3(+) T cells and amelioration of chronic colitis in IL-10(-/-) mice. Brain Behav Immun (2011) 0.94
ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. Cell Death Dis (2014) 0.94
Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol Res (2014) 0.94
A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. J Immunol Res (2014) 0.92
Suppression of vaccine immunity by inflammatory monocytes. J Immunol (2012) 0.91
Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells. J Immunol (2013) 0.90
Myeloid-derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance. Front Immunol (2012) 0.90
Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. Cancer Immunol Res (2014) 0.90
Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Mol Cell Biol (2014) 0.89
Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia. Am J Physiol Cell Physiol (2015) 0.89
Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. Oncoimmunology (2015) 0.89
Obesity-driven inflammation and cancer risk: role of myeloid derived suppressor cells and alternately activated macrophages. Am J Cancer Res (2013) 0.89
Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat Commun (2016) 0.89
Enhancing the efficacy of cancer vaccines in urologic oncology: new directions. Nat Rev Urol (2009) 0.88
The role of myeloid-derived suppressor cells in immune ontogeny. Front Immunol (2014) 0.88
Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res (2015) 0.88
Intragraft CD11b(+) IDO(+) cells mediate cardiac allograft tolerance by ECDI-fixed donor splenocyte infusions. Am J Transplant (2012) 0.88
Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. BMC Cancer (2012) 0.88
Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer. Cancer J (2013) 0.88
Molecular alterations in glioblastoma: potential targets for immunotherapy. Prog Mol Biol Transl Sci (2011) 0.86
Targeted STAT3 disruption in myeloid cells alters immunosuppressor cell abundance in a murine model of spontaneous medulloblastoma. J Leukoc Biol (2013) 0.86
The immune microenvironment of myeloma. Cancer Microenviron (2011) 0.86
Chronic alcohol consumption enhances myeloid-derived suppressor cells in B16BL6 melanoma-bearing mice. Cancer Immunol Immunother (2010) 0.86
Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs). Cancer Microenviron (2011) 0.86
Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells. Oncoimmunology (2015) 0.85
Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer. Front Oncol (2014) 0.85
Urokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1/sec. Blood (2009) 0.85
The DC-HIL/syndecan-4 pathway regulates autoimmune responses through myeloid-derived suppressor cells. J Immunol (2014) 0.85
Evolution of Our Understanding of Myeloid Regulatory Cells: From MDSCs to Mregs. Front Immunol (2014) 0.85
TGFβ in T cell biology and tumor immunity: Angel or devil? Cytokine Growth Factor Rev (2014) 0.85
Circulating myeloid-derived suppressor cells are increased and activated in pulmonary hypertension. Chest (2011) 0.84
Vaccination with embryonic stem cells protects against lung cancer: is a broad-spectrum prophylactic vaccine against cancer possible? PLoS One (2012) 0.84
Tolerance and immune suppression in the tumor microenvironment. Cell Immunol (2015) 0.84
Downregulation of CD40 expression contributes to the accumulation of myeloid-derived suppressor cells in gastric tumors. Oncol Lett (2014) 0.83
The tumor microenvironment in esophageal cancer. Oncogene (2016) 0.83
Myeloid-derived suppressor cells modulate immune responses independently of NADPH oxidase in the ovarian tumor microenvironment in mice. PLoS One (2013) 0.83
Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape. Immunol Invest (2012) 0.83
Characteristics of "Tip-DCs and MDSCs" and Their Potential Role in Leishmaniasis. Front Microbiol (2012) 0.83
Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol (2005) 9.27
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006) 7.02
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol (2005) 6.05
Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol (2004) 5.78
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood (2000) 4.78
NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol (2000) 4.75
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res (2004) 4.74
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A (1998) 4.53
Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol (2005) 4.47
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med (2006) 4.20
IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol (2003) 3.69
Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64
STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol (2005) 3.32
Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med (1999) 3.29
Ia antigen-bearing B cell tumor lines can present protein antigen and alloantigen in a major histocompatibility complex-restricted fashion to antigen-reactive T cells. J Exp Med (1982) 3.01
Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother (2003) 2.65
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood (2005) 2.60
Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol (2004) 2.54
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood (2007) 2.03
Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol (2007) 1.92
Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci U S A (1995) 1.75
Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J Immunol (2000) 1.68
B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc Natl Acad Sci U S A (1989) 1.66
Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J Immunol (2005) 1.53
Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes. Proc Natl Acad Sci U S A (1975) 1.33
Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest (2006) 1.26
Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J Immunol (2003) 1.23
In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood (2005) 1.13
Effects of L-arginine on the proliferation of T lymphocyte subpopulations. JPEN J Parenter Enteral Nutr (2001) 1.11
Tolerance and cancer: a critical issue in tumor immunology. Crit Rev Oncog (1996) 1.09
Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood (2000) 1.06
Phosphorylation of the survival kinase Akt by superoxide is dependent on an ascorbate-reversible oxidation of PTEN. Free Radic Biol Med (2007) 1.01
Myeloma proteins as tumor-specific antigens. Transplant Proc (1975) 1.00
Growth factor-induced mobilization of dendritic cells in kidney and liver of rhesus macaques: implications for transplantation. Transplantation (2007) 0.95
Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies. Blood (2003) 0.93
Differential modulation of CD4 and CD8 T-cell proliferation by induction of nitric oxide synthesis in antigen presenting cells. Transplantation (2002) 0.92
Inhibition of calcium signalling in murine splenocytes by polyamines: differential effects on CD4 and CD8 T-cells. Biochem J (1993) 0.89
Lymphoma. Curr Opin Oncol (1997) 0.82
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant (2008) 7.10
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol (2005) 6.05
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med (2006) 4.20
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res (2004) 3.94
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res (2008) 3.57
Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant (2010) 2.17
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood (2010) 1.99
A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood (2010) 1.89
Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A (2011) 1.89
High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leuk Lymphoma (2011) 1.49
Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res (2008) 1.43
Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res (2005) 1.35
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol (2011) 1.26
In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood (2005) 1.13
Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst (2008) 1.11
Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood (2002) 1.10
Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res (2012) 1.08
Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells. Nat Med (2003) 1.00
Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation. Blood (2007) 0.97
Total cost comparison in relapsed/refractory multiple myeloma. J Med Econ (2013) 0.96
Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells. Blood (2013) 0.95
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol (2012) 0.91
Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park) (2010) 0.91
Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy. Mol Cancer Ther (2012) 0.90
Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. Biol Blood Marrow Transplant (2003) 0.89
The bone marrow stroma in hematological neoplasms--a guilty bystander. Nat Rev Clin Oncol (2011) 0.89
Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol (2012) 0.89
Autologous stem cell transplantation and multiple myeloma cancer stem cells. Biol Blood Marrow Transplant (2012) 0.86
The immune microenvironment of myeloma. Cancer Microenviron (2011) 0.86
Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo. Leuk Res (2004) 0.83
Development of target-specific treatments in multiple myeloma. Br J Haematol (2010) 0.83
Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma. Br J Haematol (2011) 0.82
New Developments in the Therapy of Acute Myelocytic Leukemia. Hematology Am Soc Hematol Educ Program (2000) 0.81
Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma. Am J Hematol (2014) 0.78
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma. Int J Hematol (2012) 0.78
Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc (2010) 0.75
Lenalidomide in renal insufficiency--balancing the risks and benefits. Br J Haematol (2008) 0.75
New Treatments and Insights in Multiple Myeloma. ONS Connect (2016) 0.75
Autologous hematopoietic stem cell transplantation for patients with multiple myeloma: an overview for nurses in community practice. Clin J Oncol Nurs (2013) 0.75
Clinical updates in blood and marrow transplantation in multiple myeloma. Clin J Oncol Nurs (2013) 0.75
Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma. Semin Oncol Nurs (2017) 0.75
The Critical Role of Nurses in the Care of Patients With Multiple Myeloma. ONS Connect (2015) 0.75